← Leaderboards
Gerard J Criner
Temple University
$9,691,914
Attributed
$12,529,226
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,529,226 · 5
By mechanism
N01$6,059,529 · 2
U01$3,783,083 · 1
U10$2,686,614 · 1
M01$0 · 1
Top collaborators
- Steven R Duncan5 shared
- Daniel J Kass5 shared
- Ivan O. Rosas5 shared
Others in their field
Top investigators on “Oxygen”
- Harry B Gray · California Institute Of Technology$40,464,946
- Dennis L Matthews · University Of California-Davis$39,323,652
- Lihong Wang · Texas A&M University System$29,876,212
- Robert O Wright · Brigham And Women'S Hospital$29,689,750
- Kenneth D. Tew · Fox Chase Cancer Center$28,254,969
- Robert A Kamphaus · University Of Washington$28,160,432
Research focus
OxygenChronic Obstructive Airway DiseaseQuality Of LifeHypoxemiaLung DiseasesLungFuturePathogenesisTreatment TrialClinical TrialsResponseClinical ResearchResearch PersonnelRespiratory PhysiologyPharmaceutical PreparationsOutcome MeasureCessation Of LifeMedicalOxygen Therapy CareInvestigationLeadDyspneaHamman-Rich SyndromeAvidity
Grant awards (22)
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$700,683
U01 · FY2021 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$753,012
U01 · FY2020 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2019 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2018 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$787,346
U01 · FY2017 · HL
Long-term Oxygen Treatment Trial$6,842
N01 · FY2016 · HL · contact PI
Long-Term Oxygen Treatment Trial (LOTT) - Regional Clinical Center$291,784
N01 · FY2015 · HL · contact PI
TAS:: 75 0872:: TAS LUNG TISSUE RESEACH CONSORTIUM CLINICAL CENTER$542,181
N01 · FY2014 · HL · contact PI
OTHER FUNCTIONS: Long-Term Oxygen Treatment Trial (LOTT) - Regional Clinical Cen$995,805
N01 · FY2013 · HL · contact PI
TAS:: 75 0872:: TAS LUNG TISSUE RESEACH CONSORTIUM CLINICAL CENTER$351,271
N01 · FY2013 · HL · contact PI
Long-term Oxygen Treatment Trial$1,222,565
N01 · FY2012 · HL · contact PI
TAS:: 75 0872:: TAS LUNG TISSUE RESEACH CONSORTIUM CLINICAL CENTER$512,409
N01 · FY2012 · HL · contact PI
Long-term Oxygen Treatment Trial$1,120,685
N01 · FY2011 · HL · contact PI
TAS:: 75 0872:: TAS LUNG TISSUE RESEACH CONSORTIUM CLINICAL CENTER$497,595
N01 · FY2011 · HL · contact PI
Long-term Oxygen Treatment Trial$518,392
N01 · FY2010 · HL · contact PI
COPD Clinical Research Network & Clinical Research Skills Core Development$1,086,638
U10 · FY2007 · HL · contact PI
COPD Clinical Research Network & Clinical Research Skil*$525,748
U10 · FY2006 · HL · contact PI
COPD Clinical Research Network &Clinical Research Skil*$736,400
U10 · FY2005 · HL
COPD Clinical Research Network &Clinical Research Skil*$337,828
U10 · FY2004 · HL
NATIONAL EMPHYSEMA TREATMENT TRIAL$0
M01 · FY2002 · RR
NATIONAL EMPHYSEMA TREATMENT TRIAL$0
M01 · FY2001 · RR
NATIONAL EMPHYSEMA TREATMENT TRIAL$0
M01 · FY2000 · RR